Bonita David P purchased $20.0M of WWB (indirect holdings)

Bonita David P purchased 1,176,471 indirectly-held shares of WINDWARD BIO GROUP AG (WWB) at $17.00 ($20.00M total) on 2026-11-16.

Original reporting
SEC EDGAR · Bonita David P
Published Nov 18, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$WWB
Bullish
medium confidence
Mentioned
$WWB
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WWBBullishLow
01

Why it matters

A director and 10% owner reported an open-market purchase of 1,176,471 shares for about $20.0M, with holdings rising to 1,708,103 shares; no 10b5-1 plan is cited.

02

Market read

Traders may treat the large insider buy as a sentiment input, but it does not replace fundamental catalysts like earnings, guidance, clinical results, or financing news.

03

What to watch

No context is provided on total insider holdings, whether other insiders are buying/selling, or whether the price paid ($17) differs from recent market levels, limiting inference.

Relevance 8/10Novelty 6/10Timing: latest SEC Form 4 filed 2026-11-18, covering a 2026-11-16 purchase

Background

The article is an SEC Form 4 insider transaction disclosure for Windward Bio Group AG (WWB).

Company-level read

Ticker impact

$WWBBullishMedium confidence
Context

Windward Bio Group AG disclosed a Form 4 showing a 10% owner director bought 1,176,471 shares for about $20.0M on 2026-11-16.

Expected impact

Likely mild upward bias or support as traders interpret the large insider purchase, with limited follow-through absent other news.

Evidence & confidence

The filing is a primary-source Form 4 and the transaction size is large, but the article provides no new company-specific operating or guidance information.

Market effects

Minimal, as this is a single-company insider transaction with no sector-wide regulatory or clinical signal.

Limited, unless WWB is a widely held proxy in a specific region, which is not indicated here.

Low, since the disclosure is company-specific and does not involve cross-border deal, regulation, or macro policy.

Counterpoint

The purchase is indirect and not under a pre-arranged 10b5-1 plan, but insider buying can still reflect liquidity planning or diversification rather than a strong forward view.

Key entities

  • Windward Bio Group AG

    Subject of the Form 4 insider transaction disclosure (WWB).

  • Bonita David P

    Director and 10% owner who purchased shares indirectly.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WWBMedAI 8/10

Windward Bio closes $251.2m Nasdaq IPO with Sanofi backing

Windward Bio Group AG (Nasdaq: WWB) closed its IPO, raising $251.2m by selling 11.8m shares at $17 each, including an underwriter option. Sanofi invested $50m in a concurrent private placement. Proceeds will fund trials for lead candidates WIN378 and WIN027. The IPO priced at the midpoint of its $16-$18 range, with net proceeds estimated at $203.8m-$228.0m. Jefferies, TD Cowen, Piper Sandler, and UBS managed the offering. Short interest and insider filings show no red flags.

$WWBHighAI 9/10

Windward Bio raises $251.2M in IPO on Nasdaq

Windward Bio Group AG (WWB) raised $251.2M in its IPO on Nasdaq, selling 11.8M shares at $17 each, including underwriters' over-allotment. Sanofi invested $50M in a private placement. WWB develops antibody treatments for respiratory and skin conditions, with two candidates in clinical trials.

$WWBHighAI 9/10

Windward Bio completes $251m IPO on Nasdaq

Windward Bio Group AG (WWB) completed its IPO on Nasdaq, raising $251.2M by selling 11.8M shares at $17 each, including underwriters' options. Concurrently, it raised $50M in a private placement with Sanofi. The biotech company focuses on antibody medicines for respiratory and dermatologic diseases, with lead candidates in clinical trials.